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LMP-420, a Small Molecular Inhibitor of TNF-, Prolongs Islet
Allograft Survival by Induction of Suppressor of Cytokine Signaling-1:
Synergistic Effect With Cyclosporin-A
Nataraju Angaswamy,* Naohiko Fukami,* Venkataswarup Tiriveedhi,*
George J. Cianciolo,† and T. Mohanakumar*‡
*Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA
†Department of Pathology, Duke University Medical Center, Durham, NC, USA
‡Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA
Inflammatory insults following islet transplantation (ITx) hinders engraftment and long-term function of the
transplanted (Tx) islets. Using a murine model of ITx, we determined the role of LMP-420, a novel TNF-α
inhibitor, both individually and in combination with the immunosuppressant cyclosporine A (CSA) in islet
engraftment and survival. Diabetic C57BL/6 mice were Tx with 500 BALB/c islets under the kidney capsule.
Four cohorts were used: LMP-420 only, CSA only, combination of LMP-420 and CSA (LMP+CSA), and
control (n = 12 per cohort). Serial monitoring of blood glucose levels revealed that LMP+CSA (35 ± 5 days)
prolonged stable blood insulin levels compared to control (6 ± 4 days). Immunohistology demonstrated that
coadministration (LMP+CSA) results in a significant decrease in CD8+ T-cell infiltration (LMP+CSA: 31 ±
18 vs. control: 224 ± 51 cells, p < 0.001). Serum cytokine analysis revealed that LMP-420 administration
resulted in an increase in the anti-inflammatory cytokine IL-10 (2.5-fold), and a decrease in TNF-α (three-
fold) with no change in IL-2. However, coadministration resulted in a marked decrease in both IL-2 and
TNF-α (threefold) along with increase in IL-10 (threefold). Coadministration also demonstrated increase of
antiapoptotic SOCS-1 and Mn-SOD expression and significant reduction of donor-specific antibodies (p <
0.005). In conclusion, LMP-420 administration with CSA results in the upregulation of anti-inflammatory
and antiapoptotic mechanisms which facilitate islet allograft engraftment and survival.
Key words: LMP-420; Cyclosporin A; Islet transplantation; Type 1 diabetes mellitus;
Tumor necrosis factor-α (TNF-α)
INTRODUCTION anoxia (42,43,45). This initial insult, resulting from a
proinflammatory milieu, predisposes to alloimmune-
and autoimmune-mediated damage of the transplantedType 1 diabetes mellitus (T1DM) is an autoimmune
disease characterized by the destruction of insulin- islets (14). Therefore, one of the immediate goals in ITx
is to identify novel strategies to prevent early damage ofproducing β-islets of the pancreas (41). Parenteral insu-
lin administration still remains the major therapeutic these islets.
Among the factors that limit islet graft survival arestrategy for treatment of patients with T1DM (31). How-
ever, this approach leads to long-term complications inflammatory cytokines, mainly interleukin-1β (IL-1β),
interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-such as diabetic retinopathy, nephropathy, neuropathy,
and macrovascular disease (30). Islet transplantation α), which are released by the infiltrating mononuclear
cells (7). TNF-α inhibitors have proven efficacious(ITx) has been proposed to be an effective treatment to
achieve sustained blood glucose levels in T1DM towards the treatment and modulation of inflammatory
and autoimmune responses in diseases such as rheuma-patients. However, even with the use of immunosuppres-
sive agents, the long-term success of islet allografts still toid arthritis and psoriasis (44). LMP-420 is a novel
anti-inflammatory purine nucleobase analogue that tran-remains poor with <10% 5-year survival (21,42). One of
the major reasons for loss of islet function immediately scriptionally inhibits TNF-α production (18). LMP-420
is noncytotoxic to TNF-α-producing cells and does notposttransplant is inflammation caused by ischemia and
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bind to or interfere with the activity of preformed TNF- kit (Mercodia Inc., Winston Salem, NC). Serum
obtained (stored at −20°C) from 60–80 µl blood col-α (28). In addition, studies have shown that LMP-420
inhibits several of the IFN-γ-induced chemokines such lected by retro-orbital puncture was used. Standard insu-
lin solution and serum (25 µl) were added into aas CXC chemokine ligand-9 (CXCL-9) and CXCL-10
(17). Based on these unique properties, we postulated monoclonal anti-insulin antibody (Ab)-coated ELISA
plate along with enzyme conjugate and incubated for 2that administration of LMP-420 following ITx would be
beneficial in preventing damage to the islets and that h at room temperature. After washing six times, TMB
(3,3′,5,5″-tetramethylbenzidine) substrate (200 µl) wassuch treatment might synergize with a currently utilized
immunosuppressive regimen in prolonging islet allograft added and incubated for another 5 min. The reaction was
stopped by adding 50 µl of stopping solution and readsurvival. Our results demonstrate that administration of
LMP-420 significantly reduces early islet cell loss post- at 450 nm on a microplate reader.
Serum levels of cytokines were analyzed using a mul-Tx leading to restoration of normoglycemia in chemi-
cally induced diabetic animals. We also demonstrate that tiplex bead immunoassay (Biosource International Inc.,
Camarillo, CA) as per the manufacturer’s protocol (10).the beneficial effect of LMP-420 is mediated by its
potent anti-inflammatory and antiapoptotic pathways. Briefly, primary Ab-coated beads with standards and sam-
ples were incubated for 2 h at room temperature. TheFurthermore, LMP-420 acts synergistically with the
commonly used immunosuppressive, calcineurin inhibi- wells were washed and incubated with biotinylated Abs
for 30 min. The streptavidin-R-phycoerythrin solutiontor cyclosporin A (CSA), to further enhance the survival
of allogeneic transplanted islets. was added and read using the Luminex-xMAP-system.
MATERIALS AND METHODS
Analysis of T-Cell Frequency
Animals and Induction of Diabetes
Transplanted mice splenocytes were stimulated withSix- to 8-week-old C57BL/6 (H2b) and BALB/c
irradiated donor splenocytes; the number of T cells(H2d) mice were purchased from Jackson Laboratories.
secreting IFN-γ, IL-10, IL-4, and TNF-α was enumer-Animal studies were performed in accordance with the
ated by ELISPOT (Enzyme-linked immunosorbent spot)Animal Studies Committee, Washington University, St. (5). Briefly, Millipore MultiScreen filter plates (Milli-Louis, MO guidelines. Streptozotocin (STZ, Sigma, St.
pore Corporation, Billerica, MA) were coated overnightLouis, MO, 200 mg/kg) was administered intraperitone-
with 5 µg/ml capture mouse cytokine-specific mAb (BDally (IP) to induce diabetes in C57BL/6 mice. Nonfast-
Biosciences PharmingenTM, San Diego, CA). Subse-ing blood glucose (NFBG) was measured using tail snip
quently, 3 × 105 recipient splenocytes were cultured in(One Touch II-glucometer; Lifescan Inc., Milpitas, CA).
triplicate in the presence of irradiated donor splenocytesMice with two consecutive NFBG ≥ 400 mg/dl were (1:1 ratio). After 48–72 h, 2 µg/ml biotinylated mAbconsidered diabetic.
was added to the wells and incubated overnight. The
Islet Isolation, Transplantation, and Treatment plates were washed and 100 µl streptavidin-horseradish
Islets from murine pancreata were isolated by col- peroxidase (HRP) was added. After 2 h, the assay was
lagenase digestion and transplanted under the kidney developed by 3-amino-9-ethylcarbazole substrate reagent
capsule as described previously (29). In brief, donor and the spots were analyzed.
pancreata were digested using collagenase-XI (Sigma, 4
mg/ml). Islets washed and purified on a Ficoll-gradient Immunohistochemistry for Graft-Infiltrating CD4+
were handpicked and cultured for 24 h before Tx. The and CD8+ T Cells
reversal of diabetes was defined as a reduction in con-
Explanted kidneys containing transplanted islets were
secutive NFBG <200 mg/dl post-ITx, and rejection was
embedded in frozen tissue matrix and sections cut at adefined as an increase in NFBG >250 mg/dl. LMP-420 6-µm thickness. They were fixed in cold alcohol for 2(96–98%) was synthesized by Scynexis Inc. (Research
min (−20°C), air dried, treated with 3% H2O2, andTriangle Park, NC). The LMP-420 and CSA stock solu- blocked with biotin/avidin (Avidin/Biotin Blocking Kit;tions were made using 5% sorbitol (Sigma). The animals
Vector Laboratories, Burlingame, CA). The sections
were administered IP with either 5% sorbitol (n = 12) or
were incubated overnight with rat anti-mouse mAbsLMP-420 alone (25 mg/kg, n = 12) or CSA alone (25
against cluster of differentiation 4 (CD4) and CD8 T
mg/kg, n = 12) or a combination of LMP-420 and CSA
cells (5.0 µg/ml, BD Biosciences PharmingenTM) or iso-(both 25 mg/kg, n = 12) every day from day −1 of ITx.
type Ab (Chemicon International, Billerica, MA).
Determination of Serum Insulin, Chemokines, Washed sections were treated with biotin-conjugated
and Cytokines goat anti-rat IgG followed by streptravidin-HRP. The
presence of positive cells was detected with the DABThe concentrations of insulin were measured using
an insulin ELISA (enzyme-linked immunosorbent assay) (3,3′-diaminodbenzidine) substrate kit (BD Biosciences
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PharmingenTM). Photomicrographs were taken of 10 ran- min at 4°C. Anti-mouse phycoerythrin (PE)-labeled sec-
ondary Ab was added and further incubated for 30 min.dom field stained sections using a Nikon Eclipse 50i
microscope (10×) from each group and were analyzed The cells were then washed and read on a fluorescence-
activated cell sorter (FACS) caliber machine with instru-using morphometric software (NIS-Elements BR 3.2
program) in a blinded fashion. Sections were also pre- mental settings for mouse splenocytes.
pared from control islet grafts from nontreated mice
Statistical Analysiswith and without incubation with mouse CD4+ and
CD8+ Abs. Data are expressed as mean ± SD. Statistical differ-
ences between means were analyzed using a paired orDetermination of SOCS-1 and Mn-SOD by RT-PCR
unpaired Student’s t-test, or subjected to Scheffe’s post
and Western Blots hoc test in analysis of variance (ANOVA). Using the
A significant portion of pancreatic islet grafts can be Scheffe procedure all possible comparisons between the
destroyed by apoptosis, failing to engraft in the early means of controls with individual treatment groups (LMP-
period immediately post-ITx. Overexpression of sup- 420 alone, CSA alone, and LMP+CSA group) were con-
pressor of cytokine signaling-1 (SOCS-1) and manga- ducted. A value of p < 0.05 was considered significant.
nese-dependent superoxide dismutase (Mn-SOD) in islet
grafts achieve an antiapoptotic effect to prolong graft RESULTS
survival. Expression profiles of SOCS-1, Mn-SOD, and LMP-420 and CSA Prolongs Islet Allograft Survival
actin were analyzed by FAM-labeled RT-PCR primers
To determine the effect of LMP-420, diabetic(Applied Biosystems, Foster City, CA). Briefly, total
C57BL/6 mice were treated with LMP-420 1 day priorRNA was extracted from islet grafts using TRIzol
to ITx (500 BALB/c islets) and daily thereafter. Asreagent. The RNA was reverse transcribed and real-time
shown in Figure 1, LMP-420 significantly prolongedRT-PCR was performed using iCycler 480 Probes Mas-
islet allograft survival (22 ± 3 days), whereas the vehi-ter (Bio-Rad Laboratories, Inc., Hercules, CA). Cycling
cle-treated cohort rejected the allograft on 7 ± 2 daysconditions consisted of an initial denaturation of 95°C
post-Tx (p = 0.005). To confirm that normoglycemiafor 15 min, followed by 40 cycles of 95°C for 30 s,
was achieved by the transplanted islets, a group of LMP-followed by 61°C for 1 min.
420-treated mice was nephrectomized 14 days post-ITx.Protein levels of SOCS-1 and Mn-SOD were ana-
Nephrectomy resulted in prompt elevation of NFBG lev-lyzed by Western blot. The graft extracts were obtained
els, demonstrating that normoglycemia was beingusing 4% SDS cell lysis buffer containing protease
achieved by the transplanted islets (Fig. 1A). Dailyinhibitor cocktail. Extracts were boiled for 20 min in
administration of CSA also significantly prolonged graftsample buffer [200 mmol/L Tris (pH 6.8), 20% glycerol,
survival (24 ± 3 days) compared with control (p =2% SDS, 0.1% bromophenol blue, and 10% β-mercapto-
0.001) (Fig. 1B). These results demonstrate that LMP-ethanol], centrifuged for 30 min, and run on 4–12% gra-
420 prolongs islet allograft survival similar to thatdient Bis-Tris denaturing gels (NuPage; Invitrogen).
observed with CSA.The gels were transferred onto nitrocellulose mem-
branes, and blocked overnight with 5% nonfat milk in
Synergism of LMP-420 With Low-Dose CSAPBS-T (0.1% Tween20). Thereafter, the membranes
in Prolonging Islet Allograft Survivalwere incubated for 1 h with the appropriate Abs. After
labeling with HRP-labeled secondary Ab (1:10,000 dilu- The above results demonstrated that either LMP-420
or CSA alone significantly prolonged islet allograft sur-tion; Jackson ImmunoResearch Laboratory Inc., West
Grove, PA), the membranes were developed using vival. However, islets were rejected between days 23
and 27 post-Tx, respectively. Therefore, we sought tochemiluminescence detection kit (Millipore) and ana-
lyzed using Bio-Rad Universal Hood-II (Bio-Rad Labo- determine whether LMP-420 could act synergistically
with CSA to prolong allograft survival. Combined treat-ratories, Inc.). Morphometric analysis was performed
using the software provided by the company. ment (LMP+CSA) significantly prolonged allograft sur-
vival (35 ± 5 days; p = 0.0001) compared to control
Detection of Donor-Specific Abs (DSA) in the (Fig. 1B). These results demonstrate that combination of
Recipient’s Sera by Immunofluorescence the anti-inflammatory LMP-420 with immunosuppres-
sive agents such as calcineurin inhibitors can result inSera from sensitized C57BL/6 mice were assayed for
allo-Abs by their ability to bind BALB/c splenocytes enhanced islet graft survival. Furthermore, the sera from
the control cohort had significantly lower (p = 0.0002)using flow cytometry. Donor splenocytes (0.5 × 106)
were incubated in 50 µl fluorescence-activated cell sor- (Fig. 2A) insulin on day 8 compared with all three treat-
ment cohorts (LMP, CSA, or LMP+CSA). All threeter (FACS) buffer (5% FBS, 1% HEPES, 0.2% sodium-
azide in HBSS), containing 1:10 recipient serum for 30 treatment regimens demonstrated insulin levels up to
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Figure 1. Effect of administration of LMP-420 (A), cyclosporin A (CSA), and LMP+CSA (B) on islet allograft survival. Diabetic
C57BL/6 mice were transplanted (Tx) with 500 BALB/c islets. LMP-420 (25 mg/kg), CSA (25 mg/kg), and LMP+CSA (25 mg/
kg each) were administered by IP injection daily from day −1. Nonfasting blood glucose (NFBG) levels were monitored twice a
week by glucometer utilizing a tail snip method. Data represents mean ± SD for n = 12.
0.5 ± 0.1 pg/ml from day 8 through day 20. Addition- treatment cohorts reached pre-Tx levels by day 22, indi-
cating the rejection. In contrast, the combined treatmentally, serial histology sections of transplanted islets from
treatment groups showed positive staining for insulin on cohort retained high serum insulin levels at 32 days
post-Tx, corresponding to the graft survival curveday 8, signifying the presence of functionally healthy
islets (Fig. 2B). Insulin levels in LMP-420 and CSA (Fig. 1B).
Figure 2. Determination of insulin content in islet allograft recipient’s serum by insulin ELISA. Sera (25 µl) were added to
monoclonal anti-insulin Ab-coated ELISA plates (Mercodia Inc., Winston Salem, NC) with enzyme conjugate and incubated for 2
h. After washing (6×), they was incubated with TMB substrate (200 µ) for 5 min. After adding 50 µl of stopping solution the plate
was read at 450 nm. (B) Average numbers of insulin-positive [anti-mouse fluorescein isothiocyanate (FITC) Abs] cells in serial
histology sections of explanted grafts from control, LMP-420, CSA, and LMP+CSA treatment cohorts on day 8 post-Tx, respec-
tively (**p < 0.01).
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LMP-420, CSA, and LMP+CSA Administration Delay LMP+CSA were significantly decreased compared to
control (p = 0.0007) as well as LMP-420- or CSA-the Infiltration of Donor-Specific CD4+ and CD8+ Cells
Into the Islet Grafts treated cohorts (p = 0.004). These results demonstrate
that the infiltration of T cells into the allograft was sig-To identify the kinetics and specificity of cells infil-
nificantly reduced when LMP-420 is combined withtrating the islet allografts, we performed immunohistol-
CSA, which agrees with the prolonged islet allograftogy of the grafts on day 8 post-Tx, a time point when
survival noted with this regimen.controls start rejecting. Grafts from normoglycemic
mice were removed from all three treatment cohorts and Administration of LMP-420 or CSA and Combined
sections were stained for CD4+ and CD8+ cells. As Treatment Leads to Decreased Production
shown in Figure 3, the control grafts showed marked
of Proinflammatory Mediatorsinfiltrating CD4+ and CD8+ cells (152 ± 42 and 224 ± 51
Ischemia-reperfusion injury results in increased pro-cells, respectively, p = 0.0001) enumerated by morpho-
duction of proinflammatory cytokines that acceleratemetric analysis using NIS-Elements BR 3.2 software. In
islet cell death (5,13). To test whether LMP-420, CSA,contrast, the LMP-420 and CSA groups had 42 ± 20,
and the combination decreases the levels of inflamma-58 ± 30 and 76 ± 24, 112 ± 42 CD4+ and CD8+ cells,
tory cytokines and chemokines, sera collected from allrespectively, which though reduced was not very signifi-
four groups on day 8 post-Tx were analyzed using acantly different from controls. In contrast, infiltra-
Mouse Twenty-plex Luminex kit. As shown in Figuretions of CD4+ and CD8+ cells (22 ± 10 and 31 ± 18
4A, cytokines IL-1β and IL-4 were 1.3- to 2-fold lowercells, respectively) following combined treatment with
in all three treatment cohorts compared to control (p =
0.01). Furthermore, the T-cell proliferative cytokine IL-
2 was 2.5- to 3-fold lower in the CSA and LMP+CSA
cohorts (p = 0.01) but not in the LMP-420 treatment
cohort compared to control (144 ± 18 vs. 178 ± 21 pg/
ml, p = 0.145). In contrast, serum IL-10 levels in the
LMP-420 treatment cohort were 2.5-fold (221 ± 9.8 vs.
86 ± 14.3 pg/ml, p = 0.0001) and 1.6-fold (221 ± 9.8 vs.
136 ± 18 pg/ml, p = 0.004) higher than those in the
control and CSA administered mice, respectively. Fur-
thermore, the LMP+CSA group had 3-fold higher con-
centrations of IL-10 in their sera compared to controls
(86 ± 14.3 vs. 240.6 ± 35 pg/ml, p = 0.00001), indicat-
ing a potentially significant role for LMP-420 in increas-
ing IL-10-mediated anti-inflammatory effects. Additionally,
LMP-420 alone and LMP+CSA cohorts had 3- and 2-
fold reductions of TNF-α, respectively, in their sera
compared with the control cohort (p = 0.001). The CSA
alone-treated group also showed a decrease in TNF-α
concentration (372.3 ± 47 vs. 284.3 ± 27 pg/ml, p <
0.05) compared to controls.
Chemokines produced after Tx play a pivotal role in
recruitment of inflammatory cells (25). To determine the
effect of LMP-420 on chemokine production, sera were
analyzed for the levels of chemokines that play critical
roles in directing mononuclear cells to islet allografts
(48). As depicted in Figure 4B, LMP-420 and
LMP+CSA decreased the levels of IFN-γ-inducible pro-
tein-10 (IP-10), monocyte chemotactic protein-1 (MCP-Figure 3. Immunohistochemical staining for graft infiltrating
1), and macrophage inflammatory protein (MIP) byT cells. Cryosections of islet grafts from mice on day 8 post-
Tx were stained with rat mAbs specific to mouse CD4+ and 1.5- to 2.9-fold (p < 0.001) compared to control. In con-
CD8+ T cells. The secondary biotinylated goat anti-rat Ab was trast, there was no significant difference in the concen-
added followed by streptavidin-HRP and developed using trations of the above chemokines between control and
DAB substrate. Pictures taken (10×; Nikon Eclipse 50i micro- CSA cohorts. In addition, the concentrations of chemo-scope) were used for morphometric analysis using NIS-Ele-
kines keratinocyte chemoattractant (KC) and monokinements BR 3.2 program. The data represents mean ± SD (**p
< 0.01). induced by IFN-γ (MIG) were found to be significantly
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Figure 4. Analysis of cytokines and chemokines in transplanted mouse sera by Luminex. Sera
collected on day 8 post-Tx were used for comparative screening of various cytokine levels using
a Luminex kit according to the protocol provided by the company. The data are representative of
three separate experiments done in triplicate, and the SD bars are illustrated for the Luminex assay
(*p < 0.05, **p < 0.01).
less (1.6- to 2.5-fold, p < 0.001) in all LMP-420, CSA, 0.01), whereas the CSA alone group demonstrated a 1.3-
fold decrease (p < 0.05) (Fig. 5D). In contrast, LMP-and LMP+CSA treatment groups compared to controls.
420, CSA, and LMP+CSA groups had 2-, 1.4-, and
2.4-fold increases in the frequency of IL-10-producingLow Frequency of Donor Reactive T-Cells
T cells, respectively (Fig. 5B), compared to controls.in the Recipient Spleen After Treatment
These ELISPOT results correlated well with theWith LMP-420, CSA, and LMP+CSA
decreased levels of proinflammatory and increased lev-
To study the effect of treatment with the above agents els of anti-inflammatory cytokines in the sera of treat-
on the initiation of alloimmune responses after ITx, we ment cohorts.
determined the frequency of IL-4-, IL-10-, IFN-γ-, and
TNF-α-secreting T cells upon stimulation with donor
Enhanced SOCS-1 and Mn-SOD Levels With LMP
cells by ELISPOT on day 8 post-Tx (Fig. 5). We
and CSA Combination
observed 2.3-, 2-, and 4.1-fold reductions (p < 0.001) in
the frequency of IL-4-producing T cells in LMP-420, The results presented above indicated enhanced pro-
duction of anti-inflammatory molecules after treatmentCSA, and LMP+CSA compared with controls, respec-
tively (Fig. 5A). Similarly, the IFN-γ-producing T-cell with LMP-420 and CSA. To further determine the
potential mechanisms involved in prolonged allograftfrequency was reduced by 1.6-, 2.0-, and 2.9-fold (p <
0.001) compared with control, respectively (Fig. 5C). survival, we analyzed for the expression of SOCS-1 and
Mn-SOD, two important molecules involved in the pre-The frequency of TNF-α-producing T cells in LMP-420
and LMP+CSA administered mice was 3-fold less (p < vention of islet apoptosis. Mn-SOD is a mitochondrial
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antioxidant enzyme, increased expression of which pro- alone (4.3 ± 1.1 and 3.2 ± 0.5, respectively) (Fig.6C, D).
In addition, blinded morphometric analysis of thetects islet cells from inflammatory damage (19). The
transcription factor SOCS-1 has the ability to negatively explanted islet grafts (day 8) upon terminal deoxynucleoti-
dyl transferase dUTP nick end labeling (TUNEL) stainingregulate inflammatory cytokine signaling and can also
inhibit islets apoptosis through suppression of the Janus demonstrated 3.2-fold (12 ± 7 vs. 47 ± 13 cells)
decreased numbers of apoptotic cells in LMP+CSAkinase-signal transducer and activator of transcription
(JAK-STAT) pathway (23). The effect of combined treatment group (data not shown) compared to the con-
trol, respectively. These results further support thattreatment with LMP+CSA on the intracellular expres-
sion of these molecules was determined using both LMP-420 induces upregulation of the antiapoptotic and
anti-inflammatory transcriptional factors Mn-SOD andWestern blot and RT-PCR analyses of explanted grafts
on day 8 post-Tx. As shown in Figure 6A and B, West- SOCS-1, which is beneficial for the continued function
of transplanted islets.ern blot and densitometry analysis clearly demonstrated
that there are 2.8 ± 0.6- and 1.6 ± 0.4-fold increases in
LMP-420, CSA, and LMP+CSA Administration Delaythe levels of SOCS-1 and Mn-SOD (p < 0.001) in allo-
Formation of Abs to Donor Major Histocompatibilitygrafts from LMP-420-treated mice. Furthermore, the
Complex (MHC) (DSA) in the RecipientLMP+CSA demonstrated a very significant 6.2 ± 0.6-
and 4.3 ± 0.5-fold increase of SOCS-1 and Mn-SOD Even after continued treatment with LMP-420 and
LMP+CSA allograft rejection occurred at 23 and 35levels, respectively (p < 0.0001). RT-PCR analysis of
mRNA expression levels of SOCS-1 and Mn-SOD in days post-Tx, respectively. Studies from our laboratory,
and others, have shown that the development of DSAtreatment cohorts also demonstrated enhanced expres-
sion of these transcription factors (11.8 ± 3.1 and 6.8 ± correlates with the rejection of transplanted islets (6,29).
Therefore, sera collected at the time when glucose levels2.1, respectively) with coadministration over LMP-420
Figure 5. Determination of frequency of donor-specific T cell by ELISPOT. Recipient (C57BL/6) splenocytes (3 × 105) isolated
on day 8 post-Tx from treated and control cohorts were stimulated with irradiated donor (BALB/c) splenocytes (3 × 105) and
analyzed for production of interleukin (IL)-4 (A), IL-10 (B), interferon-γ (IFN-γ) (C), and tumor necrosis factor-α (TNF-α) (D).
The data are representative of three separate experiments performed in triplicate, and SD bars are illustrated for these assays (*p <
0.05, **p < 0.01).
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were rising were analyzed for development of DSA by and Tx procedures (4,22,38). Prior to vascularization,
transplanted islets are susceptible to inflammation andFACS. The sera of mice treated with LMP-420 or CSA
alone showed DSA on day 22 post-Tx (Fig. 7A, B). This apoptosis due to lack of nutrition and compromised
blood flow. Furthermore, the processes of coagulationparalleled the increase in NFBG and decreased insulin
levels, indicating rejection of transplanted islets. In con- and thrombosis contribute to multiple insults suffered by
the islets during early post-Tx period (38). These factorstrast, LMP+CSA-treated sera showed no Abs binding to
the donor splenocytes on day 22 (Fig. 7C), with both induce inflammation, apoptosis, and loss of islets, subse-
quently inducing adaptive immune responses that com-normoglycemia and insulin levels significantly higher,
indicating functional islets. However, the presence of promise the long-term survival. It is estimated that up to
70% of the islets are lost in the early post-Tx period,DSA was detected on day 33, when all the mice became
hyperglycemic (Fig. 7D). These results indicate that com- contributing to the need for islets from multiple pan-
creata to achieve insulin independence in a single recipi-bined treatment of LMP-420 with CSA can not only dow-
nregulate the cellular immune recognition of the graft but ent (2). Interest in clinical ITx has contributed to
development of improved harvesting, purification proce-also delay the humoral response against the graft.
dures, and new steroid-free immunosuppressive drug
DISCUSSION regimens that minimize β-cell toxicity and insulin resis-
tance (45). This has resulted in excellent rates of engraft-Islet transplants are subjected to ischemia and reper-
fusion injuries as a consequence of both their isolation ment and achievement of normoglycemia. Nonetheless,
Figure 6. RT-PCR and Western blot analysis of SOCS-1 and Mn-SOD with LMP-420 and CSA treatment. (A) Western blot
analysis of suppressor of cytokine signaling-1 (SOCS-1) and manganese-dependent superoxide dismutase (Mn-SOD) on the explan-
ted islets grafts obtained on day 8 post-Tx. Islets grafts were lysed with lysis buffer and the cytoplasmic extracts from all four
cohorts were analyzed for SOCS-1 and Mn-SOD proteins using mAbs. (B) Densitometric analysis of the protein expression (gray
bars represent SOCS-1 and hatched bars represent Mn-SOD). (C, D) RT-PCR on the mRNA extracts of the explanted islets was
performed for SOCS-1 and Mn-SOD, respectively, expression using FAM-labeled primers. Data are from four different experiments
and mean ± SD is reported.
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Figure 7. Analysis of donor-specific antibodies (DSA) in recipient sera by fluorescence-activated
cell sorter (FACS). Donor splenocytes (5 × 105) were incubated in 50 µl FACS buffer containing
1:10 dilution of recipient serum for 30 min at 4°C. Phycoerythrin (PE)-labeled secondary Ab was
added and further incubated for 30 min. The cells were washed three times with FACS buffer and
read on FACS caliber machine with instrumental setting for mouse splenocytes. (A–C) LMP-420,
CSA, and LMP+CSA on day 22. (D) LMP+CSA on day 33.
recent longer term follow-up data of ITx recipients have upregulation of both the transcriptional and protein lev-
els of SOCS-1 and Mn-SOD, two molecules previouslyshown that most recipients who are rendered free from
insulin therapy at 1 year need to reinstitute insulin ther- demonstrated to be important in allograft survival (11,24).
Initial insult to β-cells following the Tx reduces theirapy within 5 years post-Tx (42).
Traditionally, CSA is an immunomodulator that is functional efficiency. In our murine model, animals con-
tinually treated with LMP-420 and CSA showed bettereffectively utilized to prevent rejection in solid organ Tx
such as heart, liver, and kidney (3,9,12). It has a high islet allograft survival as evidenced by continued nor-
moglycemia and increased serum insulin levels (Figs. 1specificity for T lymphocytes and inhibits cell-mediated
immune responses. We previously identified a novel and 2). Proinflammatory cytokines have been shown to
play a significant role in acute graft rejection. Paschersmall molecule, LMP-420, which effectively inhibits
TNF-α production both in vitro and in vivo (17). In our et al. (33) demonstrated that anti-TNF therapy attenu-
ated the acute rejection episode. Studies have shown thatcurrent study using a murine model of ITx we demon-
strate that a combination of LMP-420 with low-dose the local expression of the inflammatory cytokine TNF-
α can impair tolerance to both auto- and alloreactivityCSA results in enhanced islet engraftment resulting in
significant prolongation of islet allograft function. This (46). Endogenous overexpression of TNF-α resulted in
accelerated rejection of transplanted islets in both auto-enhanced engraftment is a result of both downregulation
of proinflammatory cytokines/chemokines and upregula- immune and chemically induced diabetic mice, com-
pared to wild-type, by accelerating the infiltration oftion of anti-inflammatory cytokines/chemokines. More
importantly, this combined treatment results in the CD4+ and CD8+ T cells (34). Our results demonstrate
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(Fig. 3) reduced infiltration of both CD4+ and CD8+ T Previous studies from our laboratory, and studies by
others, have demonstrated that Abs to HLA in humancells by 70% on day 8 following administration of LMP-
420 alone. However, coadministration of LMP-420 and ITx has a positive correlation with graft rejection
(8,27,40). Studies in animal models of ITx also indicateCSA reduced the T-cell infiltration by 95%. This
decreased cellular infiltration and significantly decreased that Tx across sensitization to major histocompatibility
(MHC) antigens is unfavorable towards islet allograftserum TNF-α noted following administration of LMP-
420 indicated that these mechanisms play an important survival and function (6). Earlier studies in our labora-
tory demonstrated that ITx into MHC-mismatched STZ-role in the noted prolongation of islet allografts follow-
ing LMP-420 administration. treated diabetic mice resulted in the rejection of islets
with mean survival time 2 days when compared toThe role of proinflammatory responses in graft rejec-
tion is well defined (1,26). T cells are important in the unsensitized mice with mean survival time of 10 days
(16). In our current report, we demonstrate that thepathogenesis of rejection, and constitute a predominant
infiltrating cell type. However, other mononuclear cell enhanced protection and survival is also evidenced by
delayed circulating levels of DSA in the cotreatmentsubpopulations, including B cells, natural killer (NK)
cells, and monocytes/macrophages also have been shown cohort. FACS analysis demonstrated appearance of DSA
during the rejection (22 days post-Tx) in LMP-420 andto contribute in rejection (37,39). Proinflammatory cyto-
kines/chemokines released from the initial infiltrating CSA alone groups while no DSA was detected in serum
from cotreatment mice. The serum DSA developmentcells plays a major role in the continued infiltration of
cells to the graft (5,20,25,49). In this study we demon- was detected during the final stages of graft rejection
(35 days post-Tx), indicating that combined treatmentstrated that LMP-420 not only attenuates proinflamma-
tory TNF-α, IL-1β, and MCP-1 responses, but also not only downregulates cellular immune response but
also delays the humoral immune response against the graft.augments an anti-inflammatory IL-10 response (Fig. 4).
We also demonstrated that the combination of LMP-420 Our results conclusively demonstrate that LMP-420
has a potent anti-inflammatory and antiapoptotic effect.and CSA provided a synergistic effect on the cytokine
environment that facilitated islet allograft survival. LMP-420 has been further demonstrated to enhance islet
survival and function by inhibiting the alloimmuneThus, our results demonstrated that the delayed islet
allograft rejection is due to a skewing of the equilibrium humoral and cellular responses. Based on our data, we
propose a novel therapeutic application for LMP-420 intowards an enhanced IL-10 with decline in proinflam-
matory cytokines including TNF-α, IL-1β, IL-2, and combination with current therapeutic regimens using
calcineurin inhibitors, such as CSA, in the ameliorationIL-4. Based on our data, we conclude that regulatory
mechanisms were induced by LMP-420, which inhibits of rejection following human islet transplantation.
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